Home Business Support UK biology business launches new technology to alleviate asthma patients and NHS

UK biology business launches new technology to alleviate asthma patients and NHS

UK biology business launches new technology to alleviate asthma patients and NHS

MyHealth Limited, a UK Health company, have announced the launch of new and hybrid biological technology that treats severe asthma patients at home. The product aims to alleviate anticipated pressure facing the NHS this winter, with patients suffering with severe respiratory diseases expected to occupy up to half of local hospital beds.

MyAsthma Biologic

MyAsthma Biologic was commissioned as part of the NHS AAC Rapid Uptake Products programme, which aims to improve access to biologic therapies by improving pathways and current practices to achieve timely specialist patient care. The digital therapeutic supports patients in managing their asthma, and their clinical teams in managing and monitoring them remotely.

Professor James Dodd, clinical lead of North Bristol’s complex airways service adds:

“With the growing number of highly effective monoclonal antibody therapies, and the growing demand on our services, we believe that digital therapeutics like myAsthma Biologic will be increasingly important. Digital innovation has the potential to complement our dedicated multi-disciplinary team to increase capacity and enhance the support patients need to keep them well.”

Working in partnership with the University Hospital of Southampton (UHS) and the Accelerated Access Collaborative (AAC), the digital therapeutic technology offers flexible and hybrid treatment to Asthma sufferers who are at high risk of hospitalization. The product will also facilitate the collection of clinical data by automatically uploading information to the national asthma registry. Sites currently inputting data in the severe asthma registry and prescribing asthma biologics will have access to MyAsthma Biologic.

Simon Bourne, Company President at My mhealth comments:

“As a respiratory focused digital therapeutics company, we are honoured to have been chosen to roll out our product nationally to better support patients on biologics, who are living with Severe Asthma. We have already seen the huge potential of digital therapeutics to improve patients’ symptoms and quality of life and deliver efficiencies across primary and community health care services and look forward to working with the specialist severe asthma centres across the UK.’’

About My mhealth

My mhealth’s digital therapeutics have been prescribed to over 90,000 patients with chronic conditions, resulting in reduced morbidity and hospital admissions. It serves patients across a range of long-term conditions, including COPD, asthma, diabetes, and cardiovascular diseases. Real world and clinical trial evidence demonstrates the efficacy of digital interventions on the my mhealth platform.